Deals channel feed

GSK took advantage of ASCO dip to get discount on Nuvalent

3 days ago

Sciwind has two Western partners for its obesity drug, but is open to more

3 days ago

Kardigan's $320M IPO pitch: Three borrowed heart drugs, one proven cardio CEO

4 days ago

'Going for our own moonshot': Parabilis CEO on biotech's record IPO

5 days ago

Novartis and Orionis strike second molecular glue deal for $40M upfront

5 days ago

GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

6 days ago

Incyte's Meury sees $2B Vega deal as a step in blood treatments beyond Jakafi

Last week

Treeline to go public via reverse merger with Standard BioTools

Last week

J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field

Last week

Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal

Last week

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Last week

Parabilis Medicines charts $413M IPO to back peptide pipeline

Last week

Alnylam signs its first AI discovery deal with RNA specialist Inceptive

Last week

Regeneron doubles down on CytomX after other pharmas walked away

Last week

Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases

Last week

Travere pays Everest $112M upfront to grow rare kidney disease pipeline

Last week

Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech

Last week

After being ditched by Candid, Rallybio finds Avenzo to take its Nasdaq listing

2 weeks ago

Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assets

2 weeks ago

Lilly enters GLP-2 space in deal with Korea's Hanmi, also forges discovery pact with China's Haisco

2 weeks ago

Pfizer strikes Innovent deal worth up to $10.5B for a dozen cancer programs

3 weeks ago

Apogee lands $800M royalty deal with Blackstone to move Dupixent rival toward Phase 3

3 weeks ago

WuXi Bio signs manufacturing deal with Viridian as Biosecure threat continues to erode

3 weeks ago

Three vaccine biotechs to be bought by Lilly for up to $3.8B

3 weeks ago